Media & Press Releases
2022
EpicentRx Publishes Commentary in International Journal of Infectious Disease (IJID) on Need for a “Universal” Coronavirus Vaccine to be More Effective Against Novel Viral Variants
- Commentary points to need for a vaccine based on nucleocapsid vs. spike protein to make vaccine less vulnerable to mutation and provide stronger immunity to novel viral variants - Company’s development of a nucleocapsid vaccine, a recombinant replication-competent...
New industry partnership to accelerate development of Parkinson’s disease treatments
BRISBANE, AUSTRALIA, July 12, 2022 – University of Queensland researchers will partner with American biopharmaceutical company EpicentRx Inc. to evaluate new treatments for Parkinson’s disease (PD), speeding up development of potential new therapies. UQ and EpicentRx...
EpicentRx Awarded Grant from The Michael J. Fox Foundation to Evaluate Therapeutic Potential of RRx-001 in Parkinson’s Disease
The $500,000 USD grant will support study of EpicentRx’s lead small molecule inflammasome inhibitor TORREY PINES, CA, July 12, 2022 – EpicentRx Inc. (“EpicentRx”), a late-stage biopharmaceutical company developing platforms that treat and target multiple...
EpicentRx Announces Poster Presentation for Phase 2 Randomized Clinical Trial with RRx-001 as an Anti-Mucositis Agent in Locally Advanced Head and Neck Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
TORREY PINES, CA, June 1, 2022 -- EpicentRx, Inc, a privately-held clinical-stage biotechnology company at the forefront of developing oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that data...
EpicentRx Announces Oral and Poster Presentations at the 2022 American Thoracic Society (ATS) Respiratory Innovation Summit
TORREY PINES, CA, May 10, 2022 — EpicentRx, Inc., a privately-held clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that it has been...
2021
EpicentRx Publishes Proof-of-Concept Research on AdAPT-001
Oncolytic Adenovirus in Phase 1 has extended half-life TGF-ß trap LA JOLLA, Calif., December 8, 2021 -- EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other...
EpicentRx Granted New Composition of Matter Patent for Its TGF-ß Trap Fusion Protein
LA JOLLA, Calif., Nov. 22, 2021 -- EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that the United States Patent and...
EpicentRx Announces Completion of First Cohort in Phase 1 “BETA PRIME” Trial with AdAPT-001
Cancer-targeting adenovirus enhanced with a TGFβ Trap well tolerated in patients with advanced cancer TORREY PINES, Calif., Sept. 29, 2021 -- EpicentRx Inc., a leading-edge drug and device company with cancer and inflammatory disease-targeted platforms, today...
EpicentRx, Inc. in an Expansive Growth Phase
Company secures 10M US dollar growth capital term loan from Silicon Valley Bank (SVB) to accelerate development of immunotherapies for cancer AdAPT-001, a TGF-beta trap expressing oncolytic virus, designed to activate the immune system and improve checkpoint...
2020
EpicentRx Inc. and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China
SciClone granted exclusive license to co-develop and commercialize RRx-001 upon approval in the Greater China Region LA JOLLA, Calif., July 1, 2020 -- EpicentRx Inc. ("EpicentRx"), a San Diego-based clinical cancer immunotherapy company and SciClone Pharmaceuticals...
EpicentRx Appoints Life Sciences Investment Banking Veteran, Dr. Franck Brinkhaus, as President and Chief Financial Officer
TORREY PINES, Calif., June 10, 2020 -- EpicentRx, Inc., a clinical-stage pharmaceutical company on a mission to advance its portfolio of small molecule and virus-based immunotherapies for the treatment of patients with cancer and other diseases of high unmet need such...
EpicentRx Appoints Oncologist Tony Reid, M.D., Ph.D., as Chief Executive Officer (CEO)
TORREY PINES, Calif., May 29, 2020 -- EpicentRx, a next-generation clinical immuno-oncology company, today announced the appointment of physician, scientist and businessman Tony Reid, M.D., Ph.D., as the company's chief executive officer. Dr. Reid who is a co-founder...
EpicentRx IND Application for Second Immuno-oncology Program, a TGF-β Trap Adenovirus, Receives FDA Clearance
EpicentRx’s lead program is the first-in-class small molecule CD47 antagonist RRx-001 in Phase 3 for small cell lung cancer Enrollment of Phase I trial for adenovirus program AIM-001 expected to begin this year Close of recent $35M series D will advance AIM-001 and...
2019
EpicentRx Appoints Senior Life Science Financial Executive Dr. Franck Brinkhaus as Chief Financial Officer
TORREY PINES, Calif., June 10, 2020 -- EpicentRx, Inc., a clinical-stage pharmaceutical company on a mission to advance its portfolio of small molecule and virus-based immunotherapies for the treatment of patients with cancer and other diseases of high unmet need such...
EpicentRx Announces Positive Results From Phase 1 Trial of RRx-001 as First-line Treatment in Newly Diagnosed Glioblastoma
RRx-001 led to an overall survival of 21.9 months and progression-free survival of 13 months Data presented at the Society for Neuro-Oncology annual meeting LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune...
EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform
Series D Funded by an undisclosed source from Europe Total capital raised by EpicentRx approximately $77 million LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with...
EpicentRx Initiates Dosing in Phase 3 Trial of Immunotherapy RRx-001 for Third-line Small Cell Lung Cancer
LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today that it has dosed the first patient in the Phase 3 REPLATINUM trial evaluating...
EpicentRx Announces Publication of Its Positive Phase 2 3rd Line SCLC Results With RRx-001 Plus a Platinum Doublet in the British Journal of Cancer (BJC)
LA JOLLA, Calif., June 25, 2019 -- EpicentRx Inc., a clinical-stage immuno-oncology company with two platforms developed to prime and activate both innate and adaptive anticancer responses, today announced the publication of positive results from its Phase 2 clinical...
2018 & Prior
EpicentRx Announces Publication of Phase 1 Trial Results for the Anti-Cancer Agent, RRx-001, in Lancet Oncology
MOUNTAIN VIEW, Calif., Aug. 19, 2015 -- EpicentRx, Inc., a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of potent, novel anti-cancer agents, announced today the publication of positive results from...
EpicentRx Announces First Ever Treatment of Cancer Patient with Personalized, Custom-Made Viral Vaccines
SAN DIEGO, May 2, 2018 -- EpicentRx, a San Diego biotechnology company developing a next-generation immunotherapy platform of viruses that infect and kill cancer cells for the treatment of several tumor types, has developed the first ever series of oncolytic viruses...
Conferences
2022 Scientific Sessions of the National Lipid Association (NLA)
June 2022, San Francisco, California
Poster: The NLRP3 inhibitor and Nrf2 agonist, RRx-001, ameliorates non-alcoholic fatty liver disease (NAFLD/NASH) in rats
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022, Chicago, Illinois
Oral Presentation: Inflammation and Immunology: Feature Company Showcase
Poster: Phase 2 pilot trial of RRx-001 as an anti-mucositis agent in head and neck cancer patients treated with chemoradiation (PREVLAR)
American Thoracic Society (ATS) Respiratory Innovation Summit
May 2022, San Francisco, California
Oral Presentation: Inflammation and Immunology: Feature Company Showcase
Poster: The ABCs of COVID-19 Related ARDS Treatment
Poster: N-VAX, a universal coronavirus vaccine
Poster: RRx-001, an NLRP3 inflammasome inhibitor, ameliorates bleomycin-induced pulmonary fibrosis
World Vaccine & Immunotherapy, World Antiviral Congress 2021
November 2021, San Diego, California
Oral Presentation: AdAPT-001, an oncolytic adenovirus armed with a TGF-beta “trap” fusion protein
EMBO Workshop “The inflammasomes: The next frontier” 2021
September 2021, Martinsried, Germany
Abstract: The direct NLRP3 inhibitor and Phase 3 anticancer agent, RRx-001, ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model mice
TGFβ for Immuno-Oncology Drug Development Conference 2021
January 2021, Virtual
Poster: AdAPT-001, a replication competent type 5 adenovirus carrying a TGF-β “trap”, reverses resistance to a PD-L1 inhibitor in an immunocompetent mouse model
American Society for Radiation Oncology (ASTRO) 2020
October 2020, Virtual
Oral Presentation: Results of a Randomized, Open Label, Multicenter Trial Assessing the Safety, Dose and Schedule of RRx-001 (R001) in Reducing Severe Oral Mucositis (SOM) in Patients Receiving Chemoradiation (CRT) for Oral Cavity/oropharynx Squamous Cell Carcinoma (OSCC)
American Society of Clinical Oncology (ASCO) Annual Meeting 2020
June 2020, Virtual
Poster: Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule of RRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT) for advanced.
Abstract: Phase 2 Expansion Cohort in Colorectal Cancer to Evaluate the Safety and Tolerability of RRx-001 Blood Mix.
Abstract: Phase 1 Pilot Study of RRx-001 + Nivolumab in Patients with Traditionally Non-Checkpoint Inhibitor-Responsive Cancers (PRIMETIME).
Abstract: DCE-MRI Evaluation of Ten Patients with Brain Metastases Treated with RRx-001, a CD47 and PD-L1 Downregulator, in a Phase 1/2 Trial Called BRAINSTORM.
Abstract: A phase 3 trial-in-progress called REPLATINUM that compares RRx-001 + a platinum doublet to a platinum doublet in third-line or beyond small cell lung cancer.
Abstract: Correlation of decreased expression of PD-L1 on circulating tumor cells and clinical benefit in SCLC Patients treated with RRx-001, a CD47 downregulator, in a phase II trial.
Abstract: Phase 1 Study (PAYLOAD) of RRx-001 + Irinotecan in Patients with Advanced Solid Malignancies.
American Association for Cancer Research (AACR) Annual Meeting 2019
March 2019, Atlanta, Georgia
Abstract: Response to RRx-001 in SCLC is positively correlated with a reduction in CD206(+) HLA-DR(-/low) myeloid-derived suppressor cells
Society for Immunotherapy of Cancer (SITC) Annual Meeting 2018
November 2018, Washington, D.C.
Abstract: BETATRAP, a replication competent type 5 adenovirus carrying a TGF-beta trap, reverses resistance to a PD-L1 inhibitor in an immunocompetent mouse model
Society for Neuro-Oncology (SNO) 2018
November 2018, New Orleans, Louisiana
Abstract: Initial clinical and advanced imaging outcomes from a multi-institutional phase 1 dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases
American Society for Radiation Oncology (ASTRO) 2018
October 2018, San Antonio, Texas
Abstract: Initial clinical and advanced imaging outcomes from a multi-institutional phase I dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases
American Society of Clinical Oncology (ASCO) Annual Meeting 2018
June 2018, Chicago, Illinois
Abstract: QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer
Genitourinary Cancers Symposium 2018
February 2018, San Francisco, California
Abstract: Sensitization of neuroendocrine prostate cancer by RRx-001
ASCO-SITC Clinical Immuno-Oncology Symposium 2018 February 2018, Virtual
February 2018, Virtual
Abstract: RRx-001 is a phase III aerospace-derived small molecule that immunonormalizes the tumor microenvironment
Radiation Research Society (RRS) Annual Meeting 2017
October 2017, Cancun, Mexico
Abstract: Radioprotective effects of RRx-001 on the pathophysiology of the hematopoietic system using a murine radiation model
American Association for Cancer Research (AACR) Annual Meeting 2017
April 2017, Washington, DC.
Abstract: The immunomodulatory anticancer agent RRx-001 induces a vaccine-like interferon response through epigenetic induction of viral mimicry
Abstract: Epigenetic and biological effects of 5-azacytidine and RRX-001 on DLD-1 colorectal cancer cell lines
Abstract: Phase II clinical trial patient responses to the macrophage activating agent RRx-001 correlate to TGF-β pathway activation and markers for fibrosis
American Association for Cancer Research (AACR) Annual Meeting 2016
April 2016, New Orleans, Louisiana
Abstract: Enhanced uptake and accumulation of temozolomide and irinotecan in orthotopically-implanted gliomas by vascular priming with RRx-001
Abstract: RRx-001 is effective in temozolomide-sensitive and resistant GBM
Abstract: Improved statistical approaches that account for pseudoprogression in preclinical studies of RRx-001 with immunotherapies
American Society of Hematology (ASH) 2015
December 2015, Orlando, Florida
Oral Presentation: The hypoxia-selective epigenetic agent, RRx-001, triggers apoptosis and overcomes drug-resistance in multiple myeloma cells
AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2015
November 2015, Boston, Massachusetts
Abstract: RRx-001 combined with anti-PD-L1 antibody increases the complete response rate in a preclinical myeloma model
Stem Cells Regenerative Medicine Congress 2015
September 2015, Washington, D.C.
Invited Presentation: Restoring efficacy of immunotherapy treatments in oncology with radical oxygen and nitrogen based epigenetic drugs
AACR, Chromatin and Epigenetics in Cancer 2015
September 2015, Atlanta, Georgia
Abstract: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing Phase 2 colorectal cancer study, “ROCKET”
International Society for Magnetic Resonance in Medicine (ISMRM) 2015
May 2015, Toronto, Canada
Abstract: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI in preclinical tumor models
American Association for Cancer Research (AACR) Annual Meeting 2015
April 2015, Philadelphia, Pennsylvania
Abstract: Early results from a phase 2 study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer
13th International Congress on Targeted Anticancer Therapies (TAT) 2015
March 2015, Paris, France
Abstract: Early results: “ROCKET” a phase II study of RRx-001, a novel triple epigenetic inhibitor, resensitization to irinotecan in colorectal cancer
Clinical Epigenetics International Meeting (CLEPSO) 2015
March 2015, Düsseldorf, Germany
Abstract: Early results from a phase 2 study of RRx-001, a novel epigenetic modulator, show resensitization to irinotecan in colorectal cancer
4th International Workshop on Nitric Oxide in Cancer Therapy 2015
March 2015, Seville, Spain
Invited Presentation: Early results from a phase 2 study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer
AACR Translation of the Cancer Genome Conference 2015
February 2015, San Francisco, California
Abstract: RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study
17th Annual Symposium on Anti-Angiogenesis and Immune Therapies 2015
Feb 2015, La Jolla, California
Abstract: RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the phase 2 “ROCKET” study
International Society For Extracellular Vesicles (ISEV) 2014
October 2014, San Diego, California
Abstract: RRx-001 an EXO-based epigenetic anti-cancer agent in phase 2 clinical trials
American Association for Cancer Research (AACR) Annual Meeting 2014
Apr 2014, San Diego, California
Abstract: Molecular imaging of RRx-001-induced oxidative stress in Nrf2-luciferase expressing SCC VII tumors in mice
Abstract: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase
Abstract: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI in preclinical tumor models
16th International Symposium on Anti-Angiogenic Therapy 2014
February 2014, La Jolla, California
Abstract: Resensitization to previous chemotherapy with the novel hypomethylating anticancer agent RRx-001
American Chemical Society, Western Regional Meeting 2013
October 2013, Santa Clara, California
Oral Presentation: High resolution MS proves that the developmental cancer drug, RRx-001, alkylates the hemoglobin beta chain
3rd International Workshop on Nitric Oxide in Cancer Therapy 2013
May 2013, Kingston, Ontario
Abstract: RRx-001, a hypoxia activated, nitric oxide generating cytotoxic agent: Phase 1 study results
American Association for Cancer Research (AACR) Annual Meeting 2013
April 2013, Washington, D.C.
Abstract: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent
15th International Symposium on Anti-Angiogenic Therapy 2013
January 2013, La Jolla, California
Abstract: Antivascular activity of RRx-001 in SCCVII and U87 tumors
Abstract: RRx-001: A novel hypoxia activated nitric oxide generating vascular disrupting agent (VDA)
Abstract: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent
American Society of Hematology (ASH) 2012
December 2012, Atlanta Georgia
Abstract: Treatment with a novel dinitroazetidine, ABDNAZ, improves nitrite reductase activity of sickle red blood cells
American Association for Cancer Research (AACR) Annual Meeting 2012
March 2012, Chicago Illinois
Abstract: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors
American Society of Hematology (ASH) 2011
December 2011, San Diego, California
Abstract: NO or no NO, increased reduction of nitrite to nitric oxide by modified red blood cells
International Society for the Study of Xenobiotics (ISSX) 2011
April 2011, Atlanta, Georgia
Abstract: Disposition of 14C-RRx-001 in rats after a single intravenous administration and in blood from rats, dogs, monkeys, and humans
American Association for Cancer Research (AACR) Annual Meeting 2011
April 2011, Orlando, Florida
Abstract: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials’